The Canine and Feline Pancreatic Lipase Immunoreactivity (PLI) assay is a species-specific immunoassay designed to measure pancreatic lipase concentrations in serum. PLI has become one of the most valuable laboratory biomarkers for evaluating pancreatic inflammation and is an important adjunct in the diagnosis of pancreatitis in both dogs and cats.
Unlike traditional serum lipase or amylase measurements, PLI is highly specific for pancreatic tissue, providing improved diagnostic performance when pancreatic disease is suspected. When interpreted alongside the patient's clinical presentation, laboratory findings, and diagnostic imaging, PLI offers clinicians a reliable tool for investigating acute and chronic pancreatic disorders.
Pancreatitis is a common yet frequently underdiagnosed disorder in both canine and feline patients. Clinical presentation can range from mild gastrointestinal signs to severe systemic illness, making diagnosis challenging based on physical examination alone.
Measurement of serum PLI provides valuable information when pancreatitis is included among the differential diagnoses and may assist clinicians in:
✔ Evaluating patients with suspected pancreatic inflammation
✔ Supporting the diagnosis of acute or chronic pancreatitis
✔ Monitoring disease progression during treatment
✔ Assessing response to therapeutic management
✔ Differentiating pancreatic disease from other gastrointestinal disorders
Because no single diagnostic test should be interpreted in isolation, PLI results should always be considered together with clinical history, physical examination, diagnostic imaging, complete blood count, serum biochemistry, and other relevant laboratory findings.
PLI testing is recommended for dogs and cats presenting with clinical signs consistent with pancreatic disease, including:
In feline patients, pancreatitis frequently presents with vague, nonspecific clinical signs. Measurement of feline PLI may therefore provide valuable diagnostic information even when classical manifestations are absent.
Historically, serum amylase and lipase activities were routinely used to investigate pancreatic disease. However, these enzymes have limited diagnostic specificity because concentrations may be influenced by non-pancreatic disorders, reduced renal clearance, analytical variability, and other physiological factors.
The Canine and Feline PLI assays employ antibodies directed against species-specific pancreatic lipase, allowing selective measurement of pancreatic-derived enzyme concentrations and improving diagnostic confidence when pancreatitis is suspected.
✔ Quantitative measurement of pancreas-specific lipase
✔ High clinical specificity for pancreatic inflammation
✔ Supports rapid clinical decision-making
✔ Valuable for diagnosis and monitoring
✔ Species-specific measurement of pancreatic lipase
✔ Daily turnaround for faster case management
✔ Supports clinical decision-making alongside imaging and laboratory findings
The diagnosis of pancreatitis often requires a multimodal approach. PLI should be interpreted in conjunction with additional diagnostic information, including:
Combining laboratory biomarkers with diagnostic imaging increases overall diagnostic accuracy and helps clinicians distinguish pancreatic disease from other gastrointestinal or systemic disorders.
HealthGene utilizes a quantitative enzyme-linked immunosorbent assay (ELISA) for the measurement of canine and feline pancreatic lipase immunoreactivity.
The assay employs species-specific monoclonal antibodies that selectively bind pancreatic lipase, allowing accurate quantification of circulating pancreatic enzyme concentrations within validated analytical ranges.
PLI concentrations should always be interpreted within the context of the patient's clinical presentation.
Normal concentrations are generally considered inconsistent with clinically significant pancreatitis, while elevated concentrations support pancreatic inflammation. Mild or borderline elevations should be interpreted cautiously, particularly in patients with concurrent systemic disease.
Because pancreatitis may coexist with gastrointestinal, hepatic, endocrine, or renal disorders, laboratory findings should be integrated with diagnostic imaging and other clinical information before establishing a definitive diagnosis.
PLI is considered one of the most pancreas-specific laboratory biomarkers currently available; however, no laboratory test alone confirms or excludes pancreatitis. Results should always be interpreted alongside clinical findings and diagnostic imaging.
PLI reflects pancreatic inflammation but does not independently differentiate acute from chronic disease. Clinical history and diagnostic imaging remain important components of disease classification.
Serial PLI measurements may assist clinicians in monitoring disease progression and therapeutic response when interpreted together with changes in clinical status.
Yes. Feline pancreatitis frequently presents with subtle or nonspecific clinical signs such as lethargy, anorexia, or weight loss. Measurement of feline PLI can provide valuable diagnostic information in these patients.
HealthGene provides quantitative Canine and Feline Pancreatic Lipase testing to support veterinarians in the investigation of pancreatic disease. Our laboratory combines validated immunoassay methodology with comprehensive diagnostic services, enabling clinicians to integrate PLI results with clinical pathology, molecular diagnostics, microbiology, endocrinology, and advanced laboratory testing for a complete diagnostic assessment.
